<DOC>
	<DOC>NCT00348374</DOC>
	<brief_summary>The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs). Dose titrations will be provided which should allow a large proportion of subjects to reach target glycosylated hemoglobin (A1C) levels.</brief_summary>
	<brief_title>Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Adults with type 2 diabetes using LantusÂ® (insulin glargine) as their basal insulin, not at glycemic goal. lung disease current smoking or discontinued smoking within past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>type two diabetes, insulin, HbA1c</keyword>
</DOC>